Gallbladder cancers had higher rates of homologous recombination repair deficiency and ERBB2 (formerly HER2/neu) overexpression and amplification.38 Targeted therapies may be incorporated earlier in clinical care that may improve results in this cancer. This evidence concerns the gene ERBB2 and cancer.